» Articles » PMID: 27804051

Receptor-mediated Toxicity of Human Amylin Fragment Aggregated by Short- and Long-term Incubations with Copper Ions

Overview
Publisher Springer
Specialty Biochemistry
Date 2016 Nov 3
PMID 27804051
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Human amylin (hA1-37) is a polypeptide hormone secreted in conjunction with insulin from the pancreatic β-cells involved in the pathogenesis of type 2 diabetes mellitus (T2DM). The shorter fragment hA17-29 than full-length peptide is capable to form amyloids "in vitro". Here, we monitored the time course of hA17-29 β-amyloid fibril and oligomer formation [without and with copper(II)], cellular toxicity of different amyloid aggregates, and involvement of specific receptors (receptor for advanced glycation end-products, RAGE; low-affinity nerve growth factor receptor, p75-NGFR) in aggregate toxicity. Fibril and oligomer formation of hA17-29 incubated at 37 °C for 0, 48, and 120 h, without or with copper(II), were measured by the thioflavin T fluorescence assay and ELISA, respectively. Toxicity of hA17-29 aggregates and effects of anti-RAGE and anti-p75-NGFR antibodies were evaluated on neuroblastoma SH-SY5Y viability. Fluorescence assay of hA17-29 indicates an initial slow rate of soluble fibril formation (48 h), followed by a slower rate of insoluble aggregate formation (120 h). The highest quantity of oligomers was recorded when hA17-29 was pre-aggregated for 48 h in the presence of copper(II) showing also the maximal cell toxicity (-44% of cell viability, p < 0.01 compared to controls). Anti-RAGE or anti-p75-NGFR antibodies almost abolished cell toxicity of hA17-29 aggregates. These results indicate that copper(II) influences the aggregation process and hA17-29 toxicities are especially attributable to oligomeric aggregates. hA17-29 aggregate toxicity seems to be mediated by RAGE and p75-NGFR receptors which might be potential targets for new drugs in T2DM treatment.

Citing Articles

The therapeutic potential of carnosine: Focus on cellular and molecular mechanisms.

Caruso G, Di Pietro L, Cardaci V, Maugeri S, Caraci F Curr Res Pharmacol Drug Discov. 2023; 4:100153.

PMID: 37441273 PMC: 10333684. DOI: 10.1016/j.crphar.2023.100153.


Carnosine Counteracts the Molecular Alterations Aβ Oligomers-Induced in Human Retinal Pigment Epithelial Cells.

Caruso G, Fresta C, Fidilio A, Lazzara F, Musso N, Cardaci V Molecules. 2023; 28(8).

PMID: 37110558 PMC: 10146178. DOI: 10.3390/molecules28083324.


Characterization of Carnosine Effect on Human Microglial Cells under Basal Conditions.

Caruso G, Privitera A, Saab M, Musso N, Maugeri S, Fidilio A Biomedicines. 2023; 11(2).

PMID: 36831010 PMC: 9953171. DOI: 10.3390/biomedicines11020474.


Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper.

Caruso G Molecules. 2022; 27(10).

PMID: 35630780 PMC: 9143376. DOI: 10.3390/molecules27103303.


Optimized 2-methoxyestradiol invasomes fortified with apamin: a promising approach for suppression of A549 lung cancer cells.

Awan Z, Alghamdi S, Alhakamy N, Okbazghi S, Alfaleh M, Badr-Eldin S Drug Deliv. 2022; 29(1):1536-1548.

PMID: 35612292 PMC: 9154778. DOI: 10.1080/10717544.2022.2072412.


References
1.
Walsh D, Hartley D, Kusumoto Y, Fezoui Y, Condron M, Lomakin A . Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999; 274(36):25945-52. DOI: 10.1074/jbc.274.36.25945. View

2.
Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T . Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res. 2004; 23(4):129-34. View

3.
Bin Y, Li X, He Y, Chen S, Xiang J . Amyloid-β peptide (1-42) aggregation induced by copper ions under acidic conditions. Acta Biochim Biophys Sin (Shanghai). 2013; 45(7):570-7. DOI: 10.1093/abbs/gmt044. View

4.
Murphy M, Wilson Y, Vargas E, Munro K, Smith B, Huang A . Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. Neurobiol Aging. 2014; 36(2):740-52. DOI: 10.1016/j.neurobiolaging.2014.09.014. View

5.
LeVine 3rd H . Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993; 2(3):404-10. PMC: 2142377. DOI: 10.1002/pro.5560020312. View